Investor · 1 deal
Every published round Longitude Capital took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Inflazome | Unnamed stage | 17 Dec 2018 | $63m | Participant | SmartCompany (Mon 17 Dec 2018), SmartCompany (Tue 4 Dec 2018) |
Companies Longitude Capital has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Inflazome | 17 Dec 2018 | 1 | 0 |
Fund closes reported for Longitude Capital, as distinct from the investments it has made.
Companies Longitude Capital has backed that another company then bought. An exit for the holding, not a deal Longitude Capital did.
Stories naming Longitude Capital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Queensland biotech firm Inflazome has secured a large funding round led by Forbian to advance its anti-inflammatory drug candidates into clinical trials, and has hired a chief medical officer to lead that development.
Also SmartCompany